3rd Annual Immuno-Oncology Summit Europe
Date: March 19 - 23, 2018
Venue: Hilton Canary Wharf, London, UK

Conference Programs

Adoptive T-Cell Therapy 
Combination Immunotherapy 
Immunomodulatory Antibodies 

About the Event

Cambridge Healthtech Institute's Third Annual Immuno-Oncology Summit Europe returns to the heart of London's Canary Wharf for a full week of cutting-edge science and discussion. Through three back-to-back conference tracks, delegates have the opportunity to hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics. The first track, Adoptive T-Cell Therapy, will highlight advances in next-generation CAR-Ts, TCRs, and TILs, and approaches for engagement of the innate immune system. The track will present genetic engineering technologies for T cells, preclinical models, and production, and focus on specificity, off-target toxicity and safety. A dedicated track on Combination Immunotherapy will follow with a review of strategies and approaches for designing rational combination immunotherapies. This track will provide case studies of immune modulator combinations, combinations of checkpoint inhibitors with other modalities, and biomarker-and mechanism-based selection of IO combinations. The final track of the week, Immunomodulatory Antibodies, will present advances with checkpoint inhibitors, agonistic receptor engagement, NK and macrophage activation, bispecifics, and Fc-engineering technologies. Challenges in tumours unresponsive to checkpoint blockade will be addressed.

Attendee Testimonials

"The breadth and depth of the presentations was outstanding and resulted in many interesting conversations and contacts. This is what makes or breaks an event at the end of the day. The event, logistics and location were faultless too."
Senior Scientific Investigator, Systems Modeling and Translational Biology, GlaxoSmithKline

"Incredible line up of the brightest minds in immuno-oncology." 
Analyst, Aquilo Capital Management

"Thank you for the organizing such a great meeting. I enjoyed very much the wide coverage of talks from big and small pharma in the field of immuno-oncology." 
Senior Scientist, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich

View Additional Testimonials